New pill could help regrow hair in alopecia areata patients

NCT ID NCT06104839

Recruiting now Disease control Sponsor: NEXTGEN Bioscience Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called NXC736 in 73 adults with moderate to severe alopecia areata, a condition causing patchy or total hair loss. Participants are randomly assigned to receive either NXC736 or a placebo for 12 weeks. The main goal is to see if the drug can safely reduce hair loss and promote regrowth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NXC736 (oral drug)
What this could lead to: If successful, this could point toward a new oral treatment option for people with moderate to severe alopecia areata, potentially helping regrow hair.
What could go wrong: This is an early Phase 2a trial with only 73 participants, so results may not be conclusive. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

Kyung Hee University Hospital at Gangdong
RECRUITING

Seoul, 05278, South Korea
Seoul National University Hospital.
RECRUITING

Seoul, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.